Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10540348	
Filing Date		2005-06-21	
First Named Inventor Richa		rd William Arthur Luke	
Art Unit		1624	
Examiner Name	Deepak R. Rao		
Attorney Docket Number		100877-1P US	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹				Releva	s,Columns,Lines v ant Passages or I s Appear			
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation p	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	ner Cite No Publication Number Kind Code1 Date Name of Patentee or A			Releva	s,Columns,Lines v ant Passages or I as Appear	vhere Releva	unt				
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap					d buttor			
				FOREK	GN PA	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,I where Relevant Passages or Rele Figures Appear		Ţ5
	1	01/19829	wo		A2	2001-03-22	BASF Aktiengesell	schaft			
	2	01/37835	wo		A1	2001-05-31	Smithkline Beecha	m Pic			
	3	02/39954	wo		A2	2002-05-23	Smithkline Beecha Corporation	m			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

04/013141

wo

Application Number		10540348		
Filing Date		2005-06-21		
First Named Inventor	Richard William Arthur Luke			
Art Unit		1624		
Examiner Name	Deepak R. Rao			
Attorney Docket Number		100877-1P US		

AstraZeneca AB

AstraZeneca UK Limited

	5	01/72778	wo	A2	2001-10-04	BASF Aktiengesellschaft			
	6	03/022852	wo	A2	2003-03-20	GlaxoSmith KK Smithkline Beecham Corporation			
	7	03/011837	wo	A1	2003-02-13	Merck & Co Inc.			
	8	01/09121	wo	A2	2001-02-08	BASF Aktiengesellschaft			
	9	0882714	EP	B1	1998-12-09	SS Pharmaceutical Co Limited			
	10	07/33768	JP	A	1995-02-03	Kyorin Seiyaku Kk		×	
If you wisi	h to a	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cito No Dock magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, vity and/or country where publisher.							Тв	
	1 Interchim Intermediates, CHEMCATS Accession No. 2002 2408531, 9 July 2002								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								

2004-02-12

A1

	EXAMINER SIGNATURE						
Examiner Signature		Date Considered					
	reference considered, whether or not citation is in conformation and not considered. Include copy of this form with						

See Kint Codes of USPTO Patent Documents at sever USPTO GOV; or MPEP 901.04. Enter of tice that issued the document, by the two-letter of the WIPO Standard S13.) For Explaneses patent documents, the includes on the year of the register or present or serial review the patent document, and occurrent by the appropriate symbols as indicated on the document under WIPO Standard S11.6 if possible. Supplicant is to place a check mark here if English languages translation is stateded.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10540348		
Filing Date		2005-06-21		
First Named Inventor	Richa	Richard William Arthur Luke		
Art Unit		1624		
Examiner Name	Deepak R. Rao			
Attorney Docket Number		100877-1P US		

CERTIFICATION STATEMENT

Please see	37 CER	1 97	and 1 G	to make	the ann	monista	coloction(c)	r

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/37(4).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Carol A. Loeschom/	Date (YYYY-MM-DD)	2007-03-08
Name/Print	Cami A Loeschom	Registration Number	35590

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.